Table 3.
Transmission of MM2-sCJD prions to ovine PrP mice after PMCA amplification or passage through P2FJ6 cells
| Inoculum | Passage | Mean incubation timea (n/n0) | PrPres patternb | |
|---|---|---|---|---|
| Brain | Spleen | |||
| MM2-sCJD | 5 | 80 ± 1 (6/6) | T2Ov | T1Ov |
| Cloned MM2-sCJDc | 2 | 79 ± 1 (6/6) | T2Ov | T2Ov |
| MM2-sCJD → PMCA | 1 | 105 ± 1 (5/5) | T1Ov | T1Ov |
| MM2-sCJD → PMCA → tg338 brain | 2 | 84 ± 2 (6/6) | T1Ov | T1Ov |
| MM2-sCJD → PMCA → tg338 spleen | 2 | 93 ± 2 (6/6) | T1Ov | T1Ov |
| MM2-sCJD → P2FJ6 cells | 1 | 80 ± 1 (6/6) | T2Ov | T1Ov |
| Cloned MM2-sCJD → P2FJ6 cells | 1 | 75 ± 2 (6/6) | T2Ov | neg |
| MM2-sCJD → PMCA → P2FJ6 cells | 1 | 118 ± 1 (6/6) | T1Ov | T1Ov |
| MM2-sCJD → RK13 cells → tg338 | 1 | > 400 d (0/6) | neg | neg |
n/n0: number of mice with neurological disease and positive for PrPres in the brain by immunoblotting/number of inoculated mice
aDays ± SE of the mean.
b T1Ov and T2Ov refers to the migration pattern of unglycosylated PrPres at ≈ 21 kDa and ≈ 19 kDa (in the brain), respectively.
ctg338-MM2-sCJD prions were cloned by end-point titration in reporter tg338 mice and sub-passed.
Brain was used for inoculation unless mentioned
Neg: negative